celecoxib has been researched along with Genetic Predisposition in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We identified individuals with CYP2C9*2 and CYP2C9*3 genotypes (>or=1 variant allele) in the Adenoma Prevention with Celecoxib trial." | 9.14 | Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. ( Bertagnolli, MM; Breazna, A; Chan, AT; Eagle, CJ; Hawk, ET; Hsu, M; Hunter, DJ; Rosenstein, RB; Zauber, AG, 2009) |
| "Discovery phase: 1,406 Caucasian patients (139 advanced adenoma cases and 1,267 controls) from the Adenoma Prevention with Celecoxib (APC) trial were included in a genome-wide association study (GWAS) to identify variants associated with postpolypectomy disease recurrence." | 8.89 | Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. ( Baird, PN; Bertagnolli, MM; Carvajal-Carmona, LG; Chu, JH; Dunlop, M; Gibbs, P; Houlston, RS; Kubo, M; Lipton, L; Martin, NG; Matsuda, K; Montgomery, GW; Nakamura, Y; Ratain, MJ; Sieber, O; Tomlinson, I; Wang, J; Weiss, ST; Young, J; Zauber, AG, 2013) |
| "We identified individuals with CYP2C9*2 and CYP2C9*3 genotypes (>or=1 variant allele) in the Adenoma Prevention with Celecoxib trial." | 5.14 | Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. ( Bertagnolli, MM; Breazna, A; Chan, AT; Eagle, CJ; Hawk, ET; Hsu, M; Hunter, DJ; Rosenstein, RB; Zauber, AG, 2009) |
| " We then assessed the effects of celecoxib on the development of BCCs in a 3-year, double-blinded, randomized clinical trial in 60 (PTCH1(+/-)) patients with the basal cell nevus syndrome." | 5.14 | Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice. ( Aszterbaum, M; Athar, M; Barsanti, F; Bickers, DR; Cappola, C; Epstein, EH; Estevez, N; Hebert, J; Hwang, J; Khaimskiy, Y; Kim, A; Kohn, MA; Kopelovich, L; Lu, Y; McCulloch, CE; So, PL; Tang, JY; Tang, X, 2010) |
| "Discovery phase: 1,406 Caucasian patients (139 advanced adenoma cases and 1,267 controls) from the Adenoma Prevention with Celecoxib (APC) trial were included in a genome-wide association study (GWAS) to identify variants associated with postpolypectomy disease recurrence." | 4.89 | Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. ( Baird, PN; Bertagnolli, MM; Carvajal-Carmona, LG; Chu, JH; Dunlop, M; Gibbs, P; Houlston, RS; Kubo, M; Lipton, L; Martin, NG; Matsuda, K; Montgomery, GW; Nakamura, Y; Ratain, MJ; Sieber, O; Tomlinson, I; Wang, J; Weiss, ST; Young, J; Zauber, AG, 2013) |
| "No occult cases of ovarian cancer were identified and no differences in the presence of follicular cyst, hemorrhagic cysts, or inclusion cysts were noted on initial pathologic review." | 2.71 | Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent. ( Barnes, MN; Chhieng, DF; Dreher, M; Grizzle, WE; Jones, JL; Jones, L; Partridge, EE; Talley, L, 2005) |
| "Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer, is an autosomal dominant genetic condition that has a high risk of colon cancer as well as other cancers due to inherited mutations in mismatch repair (MMR) genes." | 2.52 | Advances in the study of Lynch syndrome in China. ( Lu, JY; Sheng, JQ, 2015) |
| "Celecoxib was the first COX-2 inhibitor introduced and the only remaining one on the US market." | 2.43 | Celecoxib and cardiovascular risks. ( Brophy, JM, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, J | 1 |
| Carvajal-Carmona, LG | 1 |
| Chu, JH | 1 |
| Zauber, AG | 2 |
| Kubo, M | 1 |
| Matsuda, K | 1 |
| Dunlop, M | 1 |
| Houlston, RS | 1 |
| Sieber, O | 1 |
| Lipton, L | 1 |
| Gibbs, P | 1 |
| Martin, NG | 1 |
| Montgomery, GW | 1 |
| Young, J | 1 |
| Baird, PN | 1 |
| Ratain, MJ | 1 |
| Nakamura, Y | 1 |
| Weiss, ST | 1 |
| Tomlinson, I | 1 |
| Bertagnolli, MM | 2 |
| Caimmi, SM | 1 |
| Manca, E | 1 |
| Caimmi, D | 1 |
| Marseglia, GL | 1 |
| Demoly, P | 1 |
| Gupta, A | 1 |
| Zheng, L | 1 |
| Ramanujam, V | 1 |
| Gallagher, J | 1 |
| Lu, JY | 1 |
| Sheng, JQ | 1 |
| Chan, AT | 1 |
| Hsu, M | 1 |
| Breazna, A | 1 |
| Hunter, DJ | 1 |
| Rosenstein, RB | 1 |
| Eagle, CJ | 1 |
| Hawk, ET | 2 |
| Tang, JY | 1 |
| Aszterbaum, M | 1 |
| Athar, M | 1 |
| Barsanti, F | 1 |
| Cappola, C | 1 |
| Estevez, N | 1 |
| Hebert, J | 1 |
| Hwang, J | 1 |
| Khaimskiy, Y | 1 |
| Kim, A | 1 |
| Lu, Y | 1 |
| So, PL | 1 |
| Tang, X | 1 |
| Kohn, MA | 1 |
| McCulloch, CE | 1 |
| Kopelovich, L | 1 |
| Bickers, DR | 1 |
| Epstein, EH | 1 |
| Saukkonen, K | 1 |
| Tomasetto, C | 1 |
| Narko, K | 1 |
| Rio, MC | 1 |
| Ristimäki, A | 1 |
| Xiao, Z | 1 |
| Luke, BT | 1 |
| Izmirlian, G | 1 |
| Umar, A | 1 |
| Lynch, PM | 1 |
| Phillips, RK | 1 |
| Patterson, S | 1 |
| Conrads, TP | 1 |
| Veenstra, TD | 1 |
| Greenwald, P | 1 |
| Ali, IU | 1 |
| Coulter, DM | 2 |
| Clark, DW | 2 |
| Donnelly, E | 1 |
| Roberts, RL | 1 |
| Kennedy, MA | 1 |
| Barnes, MN | 1 |
| Chhieng, DF | 1 |
| Dreher, M | 1 |
| Jones, JL | 1 |
| Grizzle, WE | 1 |
| Jones, L | 1 |
| Talley, L | 1 |
| Partridge, EE | 1 |
| Brophy, JM | 1 |
| Pilotto, A | 1 |
| Seripa, D | 1 |
| Franceschi, M | 1 |
| Scarcelli, C | 1 |
| Colaizzo, D | 1 |
| Grandone, E | 1 |
| Niro, V | 1 |
| Andriulli, A | 1 |
| Leandro, G | 1 |
| Di Mario, F | 1 |
| Dallapiccola, B | 1 |
4 reviews available for celecoxib and Genetic Predisposition
| Article | Year |
|---|---|
Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.
Topics: Adenoma; Anticarcinogenic Agents; Case-Control Studies; Celecoxib; Colorectal Neoplasms; Female; Gen | 2013 |
Advances in the study of Lynch syndrome in China.
Topics: Animals; Anticarcinogenic Agents; Asian People; Celecoxib; China; Colonoscopy; Colorectal Neoplasms, | 2015 |
Disturbance of vision by COX-2 inhibitors.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2004 |
Celecoxib and cardiovascular risks.
Topics: Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Dose-Respon | 2005 |
3 trials available for celecoxib and Genetic Predisposition
| Article | Year |
|---|---|
Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Celecoxib; Colorectal Neopla | 2009 |
Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; | 2010 |
Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: initial examination of celecoxib as a chemopreventive agent.
Topics: Adult; Anticarcinogenic Agents; Celecoxib; Cyclooxygenase Inhibitors; Female; Genetic Predisposition | 2005 |
6 other studies available for celecoxib and Genetic Predisposition
| Article | Year |
|---|---|
NSAID hypersensitivity in twins.
Topics: Adolescent; Allergens; Anti-Inflammatory Agents, Non-Steroidal; Autoantibodies; Celecoxib; Child; Ch | 2014 |
Novel Use of Pharmacogenetic Testing in the Identification of CYP2C9 Polymorphisms Related to NSAID-Induced Gastropathy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cystitis, Interstitial; Cytochrome P-450 CYP2C9; | 2015 |
Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice.
Topics: Adenoma; Angiogenesis Inhibitors; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2003 |
Serum proteomic profiles suggest celecoxib-modulated targets and response predictors.
Topics: Adenomatous Polyposis Coli; Anticarcinogenic Agents; Blood Proteins; Celecoxib; Clinical Trials, Pha | 2004 |
Linking pharmacovigilance with pharmacogenetics.
Topics: Aryl Hydrocarbon Hydroxylases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cytochr | 2004 |
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Cas | 2007 |